biostudies-literatureUnknown6(11)Kracalik I<h4>Background</h4>Data on medium-term outcomes in indivduals with myocarditis after mRNA COVID-19 vaccination are scarce. We aimed to assess clinical outcomes and quality of life at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescents and young adults.<h4>Methods</h4>In this follow-up surveillance study, we conducted surveys in US individuals aged 12-29 years with myocarditis after mRNA COVID-19 vaccination, for whom a report had been filed to the Vaccine Adverse Event Reporting System between Jan 12 and Nov 5, 2021. A two-component survey was administered, one component to patients (or parents or guardians) and one component to health-care providers, to assess patient outcomes at least 90 days since myocarditis onset. Data collected were recovery statusThe Lancet. Child & adolescent health788-798https://www.ebi.ac.uk/biostudies/studies/S-EPMC9555956biostudies-literatureOutcomes at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescents and young adults in the USA: a follow-up surveillance study.PMC9555956Neiman AMcNamara KValderrama ALRamirez-Cardenas ANale CFeyereisen MRao AShimabukuro TTLanier Gholston LSolanky DPatel SKabore CArvelo Jefferson CTaylor AKracalik IWoo JLehman JSchaeffer TGonsahn SShields KKapella BKEdwards KMazurek JMRuberg FLBasavaraju SVKluisza NWorks KShay DKGunta JBroder KRMoore MLMuseru OBarnes CJacobs Slifka KSullivan RBafford NDesai MTran CHThomas KDulski TWalter EBAssefa ADyleski BMoro PNewsome KSoslow JPantazides BTola JSu JRMoroney JFOster MEMarquez PBoles SAnugwom CNovosad SCampbell PGlover MRobinson SCreech CBCampbell MJReynolds LCortese MMStanley TSperling LThompson SKennebrew KDendy JMMagill SSBadger KLaw MCollins EGregory TMyocarditis Outcomes After mRNA COVID-19 Vaccination Investigators and the CDC COVID-19 Response TeamWiersma SMcGruder HRomanson BLang SOdom EKarol SfalseOutcomes at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescents and young adults in the USA: a follow-up surveillance study.<h4>Background</h4>Data on medium-term outcomes in indivduals with myocarditis after mRNA COVID-19 vaccination are scarce. We aimed to assess clinical outcomes and quality of life at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescents and young adults.<h4>Methods</h4>In this follow-up surveillance study, we conducted surveys in US individuals aged 12-29 years with myocarditis after mRNA COVID-19 vaccination, for whom a report had been filed to the Vaccine Adverse Event Reporting System between Jan 12 and Nov 5, 2021. A two-component survey was administered, one component to patients (or parents or guardians) and one component to health-care providers, to assess patient outcomes at least 90 days since myocarditis onset. Data collected were recovery status2022-01-01T00:00:00Z2022 Nov2025-04-03T21:30:45.797Z2025-04-03T21:30:45.797ZS-EPMC95559563615265010.1016/S2352-4642(22)00244-9